Phase II pilot study of single-agent etirinotecan pegol (NKTR-102) in bevacizumab-resistant high grade glioma

Patients with recurrence of high-grade glioma (HGG) after bevacizumab (BEV) have an extremely poor prognosis. Etirinotecan pegol (EP) is the first long-acting topoisomerase-I inhibitor designed to concentrate in and provide continuous tumor exposure throughout the entire chemotherapy cycle. Here we...

Full beskrivning

Sparad:
Bibliografiska uppgifter
I publikationen:J Neurooncol
Huvudupphovsmän: Nagpal, Seema, Recht, Cathy Kahn, Bertrand, Sophie, Thomas, Reena Parada, Ajlan, Abdulrazag, Pena, Justine, Gershon, Megan, Coffey, Gwen, Kunz, Pamela L., Li, Gordon, Recht, Lawrence D.
Materialtyp: Artigo
Språk:Inglês
Publicerad: Springer US 2015
Ämnen:
Clinical Study
Länkar:https://ncbi.nlm.nih.gov/pmc/articles/PMC4452613/
https://ncbi.nlm.nih.gov/pubmed/25935109
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s11060-015-1795-0
Taggar: Lägg till en tagg
Inga taggar, Lägg till första taggen!

Liknande verk